U
SCMP

UBS’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

UBS’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$26K Buy
3,871
+2,777
+254% +$18.4K ﹤0.01% 7678
2014
Q2 		$8K Buy
+1,094
New +$7.74K ﹤0.01% 9148

Other funds holding SCMP

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS's SCMP Position: Q3 2014 in Review

UBS increased its Sucampo Pharmaceuticals, Inc. (SCMP) stake by 254% in Q3 2014, buying an estimated $18.4K and bringing the position to 3,871 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #7678.

UBS first reported a position in SCMP in Q2 2014 and has held it in 2 quarters since. 69 funds tracked by Wall St. Rank hold SCMP as of Q3 2014.

  • UBS held 3,871 shares of Sucampo Pharmaceuticals, Inc. worth $26K as of Q3 2014.
  • UBS bought 2,777 Sucampo Pharmaceuticals, Inc. shares in Q3 2014, an estimated $18.4K.
  • Sucampo Pharmaceuticals, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7678 holding.
  • UBS first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2014 and has held it in 2 quarters since.
  • 69 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.